Summary
Vertex Pharmaceuticals Inc. reported a net loss of $44.7 million, or $0.56 per share, for the first quarter ended March 31, 2005. This marks an increase in net loss compared to the same period in the previous year, primarily due to higher research and development expenses. Despite the increased loss, total revenues saw a significant rise of approximately 63% to $28.6 million, driven by a substantial increase in collaborative research and development revenue, bolstered by new collaboration agreements signed in mid-2004. Royalty revenue also showed growth, benefiting from the sales of Lexiva/Telzir. The company maintains a strong cash position, ending the quarter with $37.4 million in cash and cash equivalents and $297.0 million in marketable securities, providing liquidity for ongoing development activities. Management anticipates continued losses but expects total revenues to be between $150 million and $160 million for the full year 2005.
Key Highlights
- 1Net loss for Q1 2005 was $44.7 million ($0.56/share), wider than Q1 2004's loss of $40.4 million ($0.52/share).
- 2Total revenues increased significantly to $28.6 million in Q1 2005, up from $17.5 million in Q1 2004, largely due to a 50% rise in collaborative R&D revenue.
- 3Research and Development (R&D) expenses rose by 38% to $57.4 million in Q1 2005, reflecting increased investment in clinical studies for compounds targeting HCV, psoriasis, and other indications.
- 4The company had $37.4 million in cash and cash equivalents and $297.0 million in marketable securities as of March 31, 2005.
- 5Vertex reaffirmed its 2005 financial guidance, projecting a full-year loss between $125 million and $135 million (excluding certain charges) and total revenues between $150 million and $160 million.
- 6The company continues to manage a significant restructuring accrual related to the Kendall Square Lease, with a remaining obligation of $52.3 million at the end of Q1 2005.